Gewinn- und Verlustrechnung von Bristol-Myers Squibb Company

AbbVie is hitting its stride now that it has transitioned past Humira's patent expiration. Medtronic is a steady dividend payer with some intriguing upside in robotics-assisted surgery.

Bristol Myers Squibb is generating more than enough earnings to cover its dividend right now. However, the company faces a daunting patent cliff.

Bristol Myers Squibb remains a Strong Buy, supported by steady performance and undervaluation despite recent underperformance versus the benchmark. BMY boasts a 4.43% forward dividend yield, over 2.7x the sector median, with 36 years of uninterrupted payments and 18 years of consecutive growth. Recent double-beat earnings and consistent estimate beats since 2024 reinforce positive sentiment and justify a premium valuation.

BMY's growth portfolio now comprises 54.1% of revenues and delivered +9% YoY growth in FQ1'26 against the legacy portfolio's slower erosion, supporting further upside to the currently conservative FY2026 guidance. Strategic partnerships with Jiangsu Hengrui, accretive M&As, and strong uptake of Opdivo Qvantig underpin the company's multi-pronged portfolio renewal efforts, despite the near-term IPRD noise. BMY's intermediate-term top/bottom-line growth prospects are likely to underwhelm due to LOE risks from Eliquis/Opdivo, albeit with secure dividend payouts at 39.2% of free cash flow.

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Bristol Myers Squibb focuses on specialized medicines in oncology and immunology, and shares sport a low valuation. Johnson & Johnson offers a diversified business model spanning innovative medicines and medical technology.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck...

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

In the latest trading session, Bristol Myers Squibb (BMY) closed at $58.56, marking a +1.81% move from the previous day.